Cite
HARVARD Citation
Koch, A. et al. (n.d.). P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies. Thorax. pp. A180-A181. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Koch, A. et al. (n.d.). P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies. Thorax. pp. A180-A181. [Online].